why AbbVie Inc. [ABBV] is a Good Choice for Investors After New Price Target of $162.50

AbbVie Inc. [NYSE: ABBV] slipped around -0.77 points on Tuesday, while shares priced at $152.83 at the close of the session, down -0.50%. The company report on January 17, 2023 that SkinMedica® Launches Even & Correct.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The Results Are Clear – A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture.

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection. Clinically proven and formulated to deliver targeted results, these three products work separately and together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads.

AbbVie Inc. stock is now -5.43% down from its year-to-date (YTD) trading value. ABBV Stock saw the intraday high of $155.10 and lowest of $152.58 per share. The company’s 52-week high price is 175.91, which means current price is +0.98% above from all time high which was touched on 01/06/23.

Compared to the average trading volume of 5.34M shares, ABBV reached a trading volume of 8278415 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about AbbVie Inc. [ABBV]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $162.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Credit Suisse have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on November 18, 2022. The new note on the price target was released on November 08, 2022, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another drop from $178 to $162, while Atlantic Equities kept a Neutral rating on ABBV stock.

The Average True Range (ATR) for AbbVie Inc. is set at 3.20, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.63. The Price to Book ratio for the last quarter was 16.92, with the Price to Cash per share for the same quarter was set at 6.78. Price to Free Cash Flow for ABBV in the course of the last twelve months was 22.19 with Quick ratio for the last quarter at 0.80.

How has ABBV stock performed recently?

AbbVie Inc. [ABBV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.46. With this latest performance, ABBV shares dropped by -7.30% in over the last four-week period, additionally plugging by 2.18% over the last 6 months – not to mention a rise of 14.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 34.82, with the RSI for the last a single of trading hit 28.63, and the three-weeks RSI is set at 40.37 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 158.61, while it was recorded at 155.09 for the last single week of trading, and 150.37 for the last 200 days.

AbbVie Inc. [ABBV]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +35.14 and a Gross Margin at +69.49. AbbVie Inc.’s Net Margin is presently recorded at +20.41.

Return on Equity for this stock inclined to 80.52, with Return on Assets sitting at 7.72.

AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.90.

Earnings analysis for AbbVie Inc. [ABBV]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to -1.74%.

Insider trade positions for AbbVie Inc. [ABBV]

There are presently around $184,707 million, or 70.90% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 156,022,414, which is approximately 1.59% of the company’s market cap and around 0.11% of the total institutional ownership; BLACKROCK INC., holding 132,960,149 shares of the stock with an approximate value of $20.32 billion in ABBV stocks shares; and STATE STREET CORP, currently with $11.84 billion in ABBV stock with ownership of nearly 0.475% of the company’s market capitalization.

Positions in AbbVie Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,421 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 49,206,065 shares. Additionally, 1,325 investors decreased positions by around 45,104,555 shares, while 364 investors held positions by with 1,114,267,610 shares. The mentioned changes placed institutional holdings at 1,208,578,230 shares, according to the latest SEC report filing. ABBV stock had 141 new institutional investments in for a total of 5,608,025 shares, while 129 institutional investors sold positions of 2,329,372 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here